Dr. O'Neil on Next Steps for Napabucasin With FOLFIRI and Bevacizumab in CRC

Bert H. O'Neil, MD
Published: Monday, Jul 10, 2017



Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the next steps for napabucasin with FOLFIRI and bevacizumab (Avastin) as treatment for patients with colorectal cancer (CRC).

A study of napabucasin with FOLFIRI and bevacizumab showed that napabucasin could be given orally at 240 mg twice daily along with a full dose of FOLFIRI.

In addition to a phase III trial that randomizes patients to either FOLFIRI or FOLFIRI plus napabucasin, the cohort of patients who were refractory to prior irinotecan was expanded. This is to confirm that the response to combination napabucasin plus FOLFIRI and bevacizumab is durable.
 
SELECTED
LANGUAGE


Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the next steps for napabucasin with FOLFIRI and bevacizumab (Avastin) as treatment for patients with colorectal cancer (CRC).

A study of napabucasin with FOLFIRI and bevacizumab showed that napabucasin could be given orally at 240 mg twice daily along with a full dose of FOLFIRI.

In addition to a phase III trial that randomizes patients to either FOLFIRI or FOLFIRI plus napabucasin, the cohort of patients who were refractory to prior irinotecan was expanded. This is to confirm that the response to combination napabucasin plus FOLFIRI and bevacizumab is durable.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x